IP Library Granted Patent US 11,384,090
Granted Patent B2
US 11,384,090 · App. 17/479,244 · Granted Jul 12, 2022

Spiropyrrolidine derived antiviral agents

Inventors: Guoqiang Wang (Belmont, MA); Ruichao Shen (Belmont, MA); Yong He (Lexington, MA); Xuri Gao (Newtonville, MA); Jun Ma (Wayland, MA); Xuechao Xing (Wilmington, MA); Hui Cao (Belmont, MA); Joseph D. Panarese (Newton, MA); Yat Sun Or (Waltham, MA)
Assignee: Enanta Pharmaceuticals, Inc.
C07D487/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,384,090
App. No.
17/479,244
Granted
Jul 12, 2022
Kind
B2
Abstract

The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

Claims (21)

1. A compound represented by Formula (XI-3),

wherein

each n is 0, 1, 2, 3, or 4;

R 3 is hydrogen, methyl or CD 3 ;

R 1 is C 1 -C 8 -alkyl or arylalkyl;

R 4 is hydrogen; and

each R 9 is halogen or C 1 -C 8 -alkoxy.

2. The compound of claim 1 , wherein the compound is

3. The compound of claim 1 , wherein the compound is

4. The compound of claim 1 , wherein the compound is

5. The compound of claim 1 , wherein the compound is

6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

7. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier or excipient.

8. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier or excipient.

9. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier or excipient.

10. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier or excipient.

11. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

12. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 2 .

13. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 3 .

14. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 4 .

15. A method of treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 5 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2021
From: WANG, GUOQIANG; SHEN, RUICHAO; HE, YONG; GAO, XURI; MA, JUN; XING, XUECHAO; CAO, HUI; PANARESE, JOSEPH D.; OR, YAT SUN
To: ENANTA PHARMACEUTICALS, INC.
Reel/Frame 058141/0152 →
Continuity (3)
Provisional Application 63117170 · Nov 23, 2020
Provisional Application 63142663 · Jan 28, 2021
Related Publication 20220162216A1 · May 26, 2022
Cited By (5)
US 12,398,147 US 12,479,854 US 12,540,141 US 12,570,663 US 12,643,905